Video summary

🦠 National Viral Hepatitis Control Programme (NVHCP) 🇮🇳 | Hepatitis B, Hep C & Elimination by 2030 📚

Main summary

Key takeaways

Educational

Main ideas and lessons conveyed

  • Viral hepatitis is presented as a “silent epidemic”: many people have no symptoms for a long time, so diagnosis is often delayed until serious liver damage has already occurred.
  • India’s NVHCP (National Viral Hepatitis Control Programme) is framed as a blueprint to eliminate viral hepatitis by 2030, aligned with global goals (notably UN SDG 3.3 and WHO elimination strategies).
  • The program emphasizes:
    • Early detection
    • Free treatment access
    • Prevention (especially HBV vaccination and safe practices)
    • Strong data systems
    • Decentralized service delivery
  • HBV and HCV have different profiles and responses:
    • HBV: intermediate endemicity, high number of carriers, vaccine available, but typically requires lifelong viral suppression (oral therapy).
    • HCV: no vaccine, but curable with direct-acting antivirals (DAAs) over 12–24 weeks.
  • The video outlines the full care pathway (“patient cascade”) from screening → confirmation → linkage → treatment → follow-up.
  • A major priority is preventing mother-to-child transmission (PMTCT) of HBV, including immediate post-birth prophylaxis for newborns.
  • NVHCP is designed as a system of interconnected verticals (management, clinical care, labs) operating at national, state, and district levels.

Methodology / operational structure (detailed)

A) Overall goal and alignment

  • Eliminate HCV as a public health threat and significantly reduce morbidity and mortality from HBV and HCV by 2030.
  • Also targets reduced risk of liver diseases linked to HBV/HCV, plus prevention intentions for:
    • Hepatitis A (HAV)
    • Hepatitis E (HEV)

B) “Six core pillars” (core objectives)

  1. Community awareness
    • Preventative messaging for general population, hotspots, and high-risk groups (HRGs).
  2. Decentralized care
    • Early diagnosis and management at all healthcare levels.
  3. Digital registry / tracking
    • Using VHIMS (web-based viral hepatitis information and management system).
  4. Standardized protocols
    • Uniform diagnostic and clinical treatment algorithms nationwide.
  5. National linkages
    • Integration with existing national programs for joint awareness, care, capacity building.
  6. Infrastructure and training (human resources)
    • Strengthen district-level capacity and training.

C) “Four core strategies” supporting the pillars

  1. Prevention first
    • Awareness and behavior change communication
    • Immunization policies
    • Blood safety and injection safety
    • WASH integration (safe water/sanitation to reduce HAV/HEV transmission)
  2. Diagnosis and treatment
    • Free-of-cost services:
      • screening
      • baseline testing
      • viral load confirmation
      • treatment:
        • DAAs for HCV
        • suppressive therapy for HBV
    • Decentralized phased rollout to urban and rural facilities (not limited to tertiary centers)
  3. Surveillance, monitoring, evaluation (M&E) and research
    • Digital tracking + integration with IDSP (Integrated Disease Surveillance Program)
  4. Training and capacity building
    • Cascade learning and institutional strengthening
    • Master trainers push protocols to state and district tiers

Prevention-first specifics (as described)

  • Awareness generation
    • Targeted behavior change communication for diverse groups.
  • HBV vaccination
    • Universal birth dose under UIP
    • Targeted vaccination for healthcare workers and high-risk groups
  • Blood safety
    • Rigorous universal screening of blood products to prevent medically caused (iatrogenic) transmission.
  • Injection safety
    • Mandating reuse prevention using RUP syringes in government facilities.
  • WASH integration
    • Align with Swachh Bharat mission for safe water/sanitation to reduce HAV/HEV.

Diagnosis and treatment specifics (as described)

  • “Simply free” approach
    • Universal access to:
      • free screening
      • baseline testing
      • viral load confirmation
    • Treatment access:
      • HCV: DAAs (12–24 weeks)
      • HBV: lifelong suppressive therapy (oral)
  • Maternal shielding (HBV-focused)
    • Screen pregnant women for HBsAg
    • Focus vaccination delivery where institutional deliveries are <80%
    • Prioritize birth dose vaccination and community engagement to improve uptake and adherence

Data systems and indicators

  • VHIMS tracks key metrics, including:
    • number of states with functional district viral hepatitis management units (DVHMUs)
    • number of diagnosed patients started on treatment (HBV/HCV)
    • tracking sustained virological response (SVR) at 12 weeks
  • Digital + paperless management information system (MIS)
    • used to maintain registries, track adherence, and monitor indicators
  • Syndromic surveillance
    • deep integration with IDSP for outbreaks and disease signals
  • Training cascade
    • over 250 master trainers from NCDC and ILBS to state/district levels

Program architecture (“trinity of care”)

A) Three synchronized verticals at every geographic tier

  1. Administrative management
  2. Clinical treatment
  3. Laboratory diagnostics

Each maps across national, state, and district levels.

B) Management structure

  • National: NVHMU (National Viral Hepatitis Management Unit)
    • housed within NHM (National Health Mission)
    • headed by a joint secretary; oversees strategy manuals and central funding
  • State: SBHMU (State Viral Hepatitis Management Unit)
    • embedded in state health society; managed by a nodal officer
    • handles state coordination, supply chain, training
  • District: DVHMU
    • supervised by a district program officer
    • handles local logistics, outreach, patient tracking, coordination with peripheral institutions

C) Clinical tiering (treatment delivery points)

  • MTCs (Model Treatment Centers)
    • at medical colleges/advanced institutes
    • handle complex cases and referrals; gastroenterologist-managed
  • TCs (Treatment Centers)
    • in district hospitals
    • medical officer-managed for uncomplicated HBV/HCV using DAAs and decentralized dispensation
  • DDUs (Decentralized Dispensation Units)
    • at subdistrict health and wellness centers (HWCs)
    • drug dispensing, adherence tracking, follow-up to prevent dropout

D) Laboratory tiering (diagnostic backbone)

  • District laboratories
    • rapid serology:
      • HBsAg
      • anti-HCV
    • baseline blood tests including platelets for APRI (A-to-platelet ratio index)
  • State reference laboratories
    • advanced molecular testing:
      • HBV DNA
      • HCV RNA viral load
    • to confirm active infection and monitor treatment efficacy
  • National reference laboratories (NRLs)
    • specialized testing, protocol development, and external quality assessment (EQA)

Patient care cascade (step-by-step workflow)

  1. Discovery / screening
    • Opportunistic screening at health facilities and/or
    • targeted outreach in hotspots
  2. Initial screening with rapid POC tests
    • rapid point-of-care serological testing for HBsAg and anti-HCV
  3. Confirmation
    • positive samples are sent for molecular testing
    • confirms active viremia
  4. Linkage
    • confirmed patients receive an NVHCP ID
    • linked to appropriate treatment facility:
      • TC or MTC
    • selection also considers APRI scoring
  5. Treatment
    • HCV: start DAAs for 12–24 weeks (free)
    • HBV: initiate lifelong suppressive therapy
  6. Follow-up
    • track SVR (sustained virological response) using the VHIMS portal

PMTCT: preventing mother-to-child transmission of HBV (HBV-focused steps)

  • Screen all pregnant women for HBsAg.
  • Ensure newborn linkage to CEmONC (Comprehensive Emergency Obstetric and Newborn Care) within a 24-hour window after birth for institutional delivery.
  • Provide newborn prophylaxis:
    • HBV birth dose vaccine in the left thigh
    • HBIG (HBV immunoglobulin) in the right thigh
  • Rationale stated:
    • if neonates acquire HBV from an infected mother, risk of chronic infection is nearly 90% without shielding.

Integration with other health systems (examples given)

  • ART centers (ERT)
    • screen PLHIV for routine HBsAg and anti-HCV
    • refer co-infected patients to MTCs
  • TI sites (targeted intervention sites)
    • outreach testing for PWID, MSM, and other HRGs via state AIDS control societies
  • ICTC
    • integrated counseling and testing centers for screening and counseling to prevent transmission
  • Blood banks and dialysis units
    • integrated screening network to protect transfusion recipients and thalassemia patients

Challenges and outlook (as described)

Strengths (internal)

  • End-to-end free services
  • Public access to advanced diagnostics and high-cost DAAs
  • Decentralized architecture (moving care from tertiary sites to district/HWC levels)
  • Strong digital backbone via VHIMS

Weaknesses (internal)

  • Silent progression delays diagnosis and narrows treatment windows
  • Gaps in access to molecular testing in remote areas
  • Human resource constraints (shortage of trained hepatologists and lab technicians)

Threats (external)

  • Social stigma and vaccine hesitancy
  • Limited awareness in some communities
  • Private sector fragmentation and inconsistent regulation

Opportunities (external)

  • Adopt stigma-free models (modeled after HIV prevention approaches)
  • Synergize with TB and AIDS programs and joint screening platforms
  • Leverage global momentum and alignment with WHO 2030 elimination targets for accountability

Speakers / sources featured (named in the subtitles)

  • Ministry of Health and Family Welfare (MoHFW), India (also referenced as MOHFW)
  • UN (United Nations) — via SDG 3.3
  • World Health Organization (WHO)
  • NCDC — National Centre for Disease Control
  • ILBS — Institute of Liver and Biliary Sciences
  • NHM — National Health Mission
  • IDSP — Integrated Disease Surveillance Programme
  • NVHCP — National Viral Hepatitis Control Programme (program itself; not a person)
  • VHIMS — Viral Hepatitis Information and Management System (system itself; not a person)
  • EQA — External Quality Assessment (process)
  • CEmONC — Comprehensive Emergency Obstetric and Newborn Care
  • ERT / ART centers — Antiretroviral therapy centers (system/program)
  • ICTC — Integrated Counseling and Testing Centre
  • NACP — National AIDS Control Programme
  • TB — Tuberculosis (referenced as part of national strategic plans)
  • Swachh Bharat mission

No individual human speaker is explicitly identified by name in the subtitles.

Original video